Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TaBleMM: Talquetamab and Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma
NCT07720843Phase 1Not yet recruiting
- Sponsor
- Montefiore Medical Center
- Start
- Sep 2026
- Primary completion
- Mar 2030
01
Overview
Phase 1, open-label, single-arm trial of talquetamab and belantamab mafodotin in multiple myeloma (MM), sponsored by Montefiore Medical Center. Primary endpoints: Frequency and severity of treatment emergent adverse events at 28 days and Maximum tolerated dose at 28 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
talquetamabbelantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07720843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07720843.